Program Description
Targeted therapies are transforming early-stage breast cancer treatment, but they require complex adjuvant treatment recommendations based on individual factors. Oncology pharmacists play a crucial role in treatment planning, but often struggle to keep up with emerging evidence and treatment guidelines. Adjuvant therapies require careful safety evaluation and effective adverse effect (AE) management. Pharmacists can enhance patient outcomes through education, AE monitoring, and proactive adherence interventions. This session will emphasize the expanding role of targeted therapies, including CDK4/6 inhibitors and PARP inhibitors, in the adjuvant setting. Opportunities for pharmacists to develop expertise in identifying high-risk disease characteristics, understanding the pharmacologic differentiators of CDK4/6 inhibitors, and applying appropriate mutational testing practices will be featured through case-based discussions.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: July 25, 2025
Expiration date: July 25, 2026
Time to complete activity: 0.75 hour
Learner level: Intermediate, Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze the latest clinical trial evidence and updated treatment guidelines for hormone receptor-positive (HR+) early-stage breast cancer, including the role of targeted therapies
- Explore disease-specific risk assessments and treatment guidelines to support individualized recommendations for adjuvant therapy in HR+ early-stage breast cancer
- Examine key adverse effect management and patient counseling considerations for targeted therapies in HR+ early-stage breast cancer, emphasizing the differences compared with counseling for those with metastatic disease
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here